Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Glaukos’ iDose TR Hits the Commercial Market
Glaukos Corporation’s iDose TR, using Celanese’s VitalDose EVA (Ethylene Vinyl Acetate), to provide sustained drug release for the treatment of glaucoma has officially entered the commercial market. Having received FDA approval in December, iDose TR represents a notable departure from…
Study Uncovers Eye’s Defense Against Brain Infections
In a study published in the journal Nature, researchers have found that vaccines injected into the eyes of mice can effectively combat the herpes virus, a leading cause of brain encephalitis. Contrary to expectations, the vaccine triggers an immune response…
FDA Recalls Some Eye Ointments Over Infection Risk
Eye ointment products manufactured in India and sold in the United States at major retailers like Walmart and CVS are being recalled due to a danger of infection. Brassica Pharma Pvt. Ltd., based in Maharashtra, India, announced the recall of…
CorNeat Vision Introduces CorNeat EverPatch in the U.S.
CorNeat Vision has launched the CorNeat EverPatch in the United States, a novel synthetic tissue-integrating matrix poised to transform ophthalmic surgeries. Endorsed by leading surgeons across the US, this FDA-cleared device marks a significant advancement in addressing complications associated with…
Amring Names Dr. Donnenfeld as U.S. Advisory Board Chair
Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V., announced the appointment of Dr. Eric D. Donnenfeld, a distinguished figure in ophthalmology, as the Chair of its U.S. Medical Advisory Board (MAB). This strategic decision comes as the company gears…
Dry Eye Disease in Postmenopausal Women
A common ocular problem is dry eye syndrome. Women are more likely to acquire dry eye syndrome and its accompanying detrimental implications on their general eye health, especially menopausal women with comorbidities. One of the most common ocular disorders is…
Innovent’s Phase 3 TED Treatment Success in China
Innovent Biologics announced the successful achievement of the primary endpoint in the phase 3 registrational study, RESTORE-1, of IBI311 in China. This recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody marks a pivotal advancement in the treatment of thyroid eye…
Dr. Arshad Khanani Joins Ophtea as Chief Medical Advisor
Opthea Limited announced Dr. Arshad M. Khanani, MD, MA, FASRS, as its new Chief Medical Advisor. Dr. Khanani, renowned in retina specialization and clinical research, brings a wealth of expertise from his tenure at Sierra Eye Associates and his academic…
MACUSTAR Extends Systematic AMD Research
The MACUSTAR consortium, led by the Department of Ophthalmology at the University Hospital Bonn (UKB), is extending its Europe-wide clinical study on age-related macular degeneration (AMD). The primary focus of the extension is to garner further insights into the intermediate…
FDA Approves XDEMVY for Demodex Blepharitis
Tarsus Pharmaceuticals has received FDA approval for XDEMVY(TM) (lotilaner ophthalmic solution) 0.25% to treat Demodex blepharitis, making it the first and only FDA-approved treatment directly targeting Demodex mites, the underlying cause of the condition. The approval was based on the…